Nalaganje...
Anti-human CD40 monoclonal antibody therapy is potent without FcR crosslinking
Antibody agonists targeting tumor necrosis factor (TNF) superfamily receptors, including CD40, are being tested therapeutically as anticancer agents. Studies in mice have shown that anti-CD40 monoclonal antibody (mAb) requires Fc-receptor (FcR) engagement to activate antitumor immunity. In contrast,...
Shranjeno v:
| Main Authors: | , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Landes Bioscience
2014
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4091558/ https://ncbi.nlm.nih.gov/pubmed/25097801 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/onci.28610 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|